← SynDRA
LIFIRAFENIB
SynDRA canonical compound SYN0039327 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | BRAF | EGFR |
|---|
| Mechanism of action | RAF inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BRAF INHIBITOR
- Serine/threonine-protein kinase B-raf inhibitor
- RAF inhibitor
Cross-references
Synonyms
- Beigene-283
- BGB-283
- Bgb 283
- lifirafenibum
- Begeine-283
- RefChem:924746
- BGB283
- Lifirafenib [USAN]
- UNII-8762XZS5ZF
- compound 2.2b
- LIFIRAFENIB [INN]
- Lifirafenib (USAN/INN)
- BGB-283;Beigene-283
- LIFIRAFENIB [WHO-DD]
- GTPL8958
- orb1146515
- orb1905876
- SCHEMBL15085288
- SCHEMBL29358338
- SCHEMBL29464034
- SCHEMBL29749194
- C25H17F3N4O3
- NGFFVZQXSRKHBM-FKBYEOEOSA-N
- BDBM372968
- GLXC-15416
- EX-A1473
- US9895376, Compound 2.2b
- WHC09077
- WHC09079
- Lifirafenib;BGB-283;Beigene-283
- BDBM50453816
- WHO 10554
- AKOS040745015
- CS-6308
- AC-35880
- AC-36373
- DA-71454
- HY-18957
- MS-28874
Look up LIFIRAFENIB in the interactive SynDRA portal →